目的 对中药方剂治疗溃疡性结肠炎的系统评价的方法学质量和结局指标的可信度进行再评价，为临床治疗溃疡性结肠炎提供更加科学的依据。方法 在中国知网、万方数据库、维普数据库、PubMed数据库中检索有关中药方剂治疗溃疡性结肠炎的系统评价及Meta分析，检索时限均为建库至2019年2月1日。两名研究者分别独立进行文献筛选和资料提取，运用AMSTAR2量表评价纳入系统评价的方法学质量，同时采用GRADE系统对结局指标进行证据质量分级。结果 最终纳入8篇系统评价，所有系统评价均对原始研究进行了偏倚风险评估；AMSTAR2评分显示，4篇为低质量，4篇为极低质量；GRADE评级结果显示，所有结局指标中8个为高等级，11个为中等级，11个为低级，2个为极低级。结论 目前中药方剂治疗溃疡性结肠炎的系统评价的方法学质量较低，但其结局指标的可靠程度相对较高，可供指南撰写者和临床证据使用者参考。
Objective To re-evaluate the methodological quality and the reliability of outcome measures of systematic reviews (SRs) on traditional Chinese medicine prescriptions in the treatment of ulcerative colitis, and to provide a scientific basis for the treatment of ulcerative colitis in clinical practice. Methods CNKI, Wanfang Data, VIP, and PubMed were searched for SRs and meta-analyses on the clinical effect of traditional Chinese medicine prescriptions in the treatment of ulcerative colitis published up to February 1, 2019. Two reviewers independently performed literature screening and data extraction and assessed the methodological quality of SRs using the AMSTAR2 tool, and the GRADE system was used to assess the quality grade of outcome measures. Results A total of 8 SRs were included, and the risk of bias was evaluated for primary studies. The results of AMSTAR2 showed that 4 SRs had low quality and 4 had very low quality, and the results of GRADE showed that among all outcome measures, 8 had a high grade, 11 had a medium grade, 1 had a low grade, and 2 had a very low grade. Conclusion Current SRs on the clinical effect of traditional Chinese medicine prescriptions in the treatment of ulcerative colitis have low methodological quality, but the outcome measures have relatively high reliability and can thus be used as a reference for guideline authors and clinical evidence users.
刘洪武,黎丽群,龚潇坤,岑前丽,谢宜春,余 良,谭金晶,黄晓燕,刘 倩,谢 胜.中药方剂治疗溃疡性结肠炎的系统评价再评价[J].安徽中医药大学学报,2020,39(1):88-93复制